UY35686A - Construcciones del factor de diferenciación de crecimiento 15 (gdf-15) - Google Patents

Construcciones del factor de diferenciación de crecimiento 15 (gdf-15)

Info

Publication number
UY35686A
UY35686A UY0001035686A UY35686A UY35686A UY 35686 A UY35686 A UY 35686A UY 0001035686 A UY0001035686 A UY 0001035686A UY 35686 A UY35686 A UY 35686A UY 35686 A UY35686 A UY 35686A
Authority
UY
Uruguay
Prior art keywords
constructions
gdf
differentiation factor
growth differentiation
gdf15
Prior art date
Application number
UY0001035686A
Other languages
English (en)
Inventor
Xiong Yumei
Zhang Yi
Jackie Z Sheng
Veniant-Ellison Murielle
Shimamoto Grant
Min Xiaoshan
Wang Zhulun
Tang Jie
Mock Marissa
Walker Kenneth
Hamburger Agnes Eva
Kannan Gunasekaran
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51358091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35686(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY35686A publication Critical patent/UY35686A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Construcciones que comprenden GDF15, y mutantes del mismo. En diferentes formas de realización las construcciones que comprenden GDF15, y mutantes del mismo, pueden usarse en el tratamiento o alivio de un trastorno metabólico. En diferentes formas de realización la enfermedad o trastorno metabólico es diabetes tipo 2, obesidad, dislipidemia, niveles elevados de glucosa, niveles elevados de insulina y nefropatía diabética.
UY0001035686A 2013-07-31 2014-07-31 Construcciones del factor de diferenciación de crecimiento 15 (gdf-15) UY35686A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361860723P 2013-07-31 2013-07-31

Publications (1)

Publication Number Publication Date
UY35686A true UY35686A (es) 2015-01-30

Family

ID=51358091

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035686A UY35686A (es) 2013-07-31 2014-07-31 Construcciones del factor de diferenciación de crecimiento 15 (gdf-15)

Country Status (35)

Country Link
US (3) US9862752B2 (es)
EP (2) EP3027642B1 (es)
JP (4) JP6509852B2 (es)
KR (3) KR20240000642A (es)
CN (2) CN113527512A (es)
AP (1) AP2016009011A0 (es)
AR (1) AR097181A1 (es)
AU (1) AU2014296107B2 (es)
BR (1) BR112016002213A2 (es)
CA (1) CA2918624C (es)
CL (1) CL2016000249A1 (es)
CR (1) CR20160097A (es)
CY (1) CY1123836T1 (es)
DK (1) DK3027642T3 (es)
EA (2) EA202092386A1 (es)
ES (1) ES2828670T3 (es)
HK (1) HK1225738A1 (es)
HU (1) HUE050630T2 (es)
IL (1) IL243749B (es)
JO (1) JO3566B1 (es)
LT (1) LT3027642T (es)
MA (1) MA38873B1 (es)
MX (2) MX369152B (es)
NZ (2) NZ754961A (es)
PE (1) PE20160189A1 (es)
PH (1) PH12016500208A1 (es)
PL (1) PL3027642T3 (es)
PT (1) PT3027642T (es)
SG (1) SG11201600713RA (es)
SI (1) SI3027642T1 (es)
TN (1) TN2016000035A1 (es)
TW (1) TWI648401B (es)
UA (1) UA116665C2 (es)
UY (1) UY35686A (es)
WO (1) WO2015017710A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
BR112014018575A2 (pt) * 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
PT3027642T (pt) 2013-07-31 2020-10-30 Amgen Inc Construtos do fator 15 de diferenciação de crescimento (gdf-15)
JP2015182969A (ja) * 2014-03-21 2015-10-22 四国化成工業株式会社 トリアゾールシラン化合物、該化合物の合成方法及びその利用
WO2015198199A1 (en) * 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN106459222A (zh) 2014-06-24 2017-02-22 诺和诺德股份有限公司 Mic‑1融合蛋白及其用途
CN106573966B (zh) 2014-07-30 2022-03-01 Ngm生物制药有限公司 用于治疗代谢异常的组合物和方法
MD20170035A2 (ro) 2014-10-31 2017-09-30 Ngm Biopharmaceuticals Inc Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
TWI815793B (zh) 2016-03-31 2023-09-21 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
KR102010652B1 (ko) * 2017-08-21 2019-08-13 서울대학교병원 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법
CN111163795A (zh) 2017-09-10 2020-05-15 诺沃挪第克公司 用于治疗肥胖症的mic-1和glp-1
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
AU2019253462A1 (en) * 2018-04-09 2020-11-26 Amgen Inc. Growth differentiation factor 15 fusion proteins
KR20210031932A (ko) * 2018-07-13 2021-03-23 젠맵 에이/에스 Cd38 항체의 변이체 및 그의 용도
SG11202103990QA (en) 2018-10-22 2021-05-28 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
AU2020260931B2 (en) * 2019-04-23 2023-08-24 Lg Chem, Ltd. Fusion polypeptide comprising Fc region of immunoglobulin and GDF15
US20220259329A1 (en) 2019-06-07 2022-08-18 Amgen Inc. Bispecific binding constructs
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
EP4065597A4 (en) * 2019-11-26 2024-01-24 Yuhan Corp LONG-ACTING GDF15 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION THEREFROM
JP2023505833A (ja) * 2019-12-11 2023-02-13 エルジー・ケム・リミテッド Ｏ－グリコシル化可能なポリペプチド領域およびｇｄｆ１５を含む融合ポリペプチド
CN114981297A (zh) 2019-12-23 2022-08-30 戴纳立制药公司 颗粒蛋白前体变体
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing Ql Biopharmaceutical Co Ltd FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
EP4237438A1 (en) 2020-10-27 2023-09-06 Beijing QL Biopharmaceutical Co., Ltd. Fusion proteins of gdf15 and use thereof
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
KR20240049337A (ko) * 2021-08-24 2024-04-16 선샤인 레이크 파르마 컴퍼니 리미티드 Gdf15 융합 단백질 및 이의 용도
WO2023152698A1 (en) 2022-02-10 2023-08-17 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN115028726B (zh) * 2022-03-31 2024-01-09 浙江特瑞思药业股份有限公司 一种抗pd-1纳米抗体及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
WO1999006445A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
CN1341121A (zh) * 1999-01-07 2002-03-20 利思进药品公司 作为Fc融和蛋白之抗肥胖蛋白质的表达和外运
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
JP2004528014A (ja) 2000-12-07 2004-09-16 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１融合タンパク質
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
WO2002072608A2 (en) 2001-03-09 2002-09-19 University Of Chicago POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
JP4422949B2 (ja) 2001-06-26 2010-03-03 武田薬品工業株式会社 ＴＧＦ−βスーパーファミリー産生・分泌促進剤
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7101852B2 (en) 2003-05-30 2006-09-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment and prevention of restenosis
CA2526669A1 (en) * 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
AU2004282984B2 (en) * 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
EP2774620A1 (en) 2004-04-13 2014-09-10 St Vincent's Hospital Sydney Limited Method for modulating weight loss
US20090042780A1 (en) * 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
WO2006020884A2 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
EP1954714A2 (en) * 2005-11-10 2008-08-13 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
CN1974601A (zh) * 2005-11-28 2007-06-06 上海新生源医药研究有限公司 一种新型Fc融合蛋白及其生产方法
CA2666599A1 (en) * 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EP2187933A4 (en) 2007-08-16 2010-12-08 St Vincents Hosp Sydney AGENTS AND METHODS FOR MODULATING MACROPHAGE INHIBITORY CYTOKINE ACTIVITY (MIC-1)
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
EP2279419A1 (en) 2008-05-20 2011-02-02 Roche Diagnostics GmbH Gdf-15 as biomarker in type 1 diabetes
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
US20120107420A1 (en) 2008-10-31 2012-05-03 St Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
ES2688978T3 (es) 2009-11-23 2018-11-07 Amgen Inc. Anticuerpo monomérico Fc
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
EP2506861A1 (en) * 2009-12-02 2012-10-10 Amgen Inc. Binding proteins that bind to human fgfr1c, human b-klotho and both human fgfr1c and human b-klotho
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
ES2526541T3 (es) 2010-07-12 2015-01-13 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
ES2526981T3 (es) 2010-07-12 2015-01-19 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
CN103080746B (zh) 2010-08-26 2015-07-15 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
EP2635607B1 (en) * 2010-11-05 2019-09-04 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
CA2830254C (en) 2011-03-16 2019-09-10 Amgen Inc. Fc variants
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
PT2697257T (pt) * 2011-04-13 2016-12-28 Bristol Myers Squibb Co Proteínas de fusão fc compreendendo novos ligantes ou arranjos
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2859667C (en) * 2011-12-20 2022-05-24 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
BR112014018575A2 (pt) * 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CN114163530A (zh) * 2012-04-20 2022-03-11 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
CA2896076C (en) 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
WO2014120619A2 (en) * 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
PT3027642T (pt) * 2013-07-31 2020-10-30 Amgen Inc Construtos do fator 15 de diferenciação de crescimento (gdf-15)
JP6675333B2 (ja) 2014-06-23 2020-04-01 ノバルティス アーゲー 部位特異的タンパク質修飾
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2015198199A1 (en) * 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
CN106459222A (zh) 2014-06-24 2017-02-22 诺和诺德股份有限公司 Mic‑1融合蛋白及其用途
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
EP3463412A1 (en) 2016-05-24 2019-04-10 Novo Nordisk A/S Mic-1 compounds and use thereof
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法

Also Published As

Publication number Publication date
SG11201600713RA (en) 2016-02-26
KR102616674B1 (ko) 2023-12-29
US9862752B2 (en) 2018-01-09
JO3566B1 (ar) 2020-07-05
TW201602345A (zh) 2016-01-16
PL3027642T3 (pl) 2021-01-11
TN2016000035A1 (en) 2017-07-05
WO2015017710A1 (en) 2015-02-05
PH12016500208B1 (en) 2016-04-25
JP2019178132A (ja) 2019-10-17
JP2016532690A (ja) 2016-10-20
MA38873B1 (fr) 2018-11-30
NZ754961A (en) 2022-04-29
US20180079790A1 (en) 2018-03-22
ES2828670T3 (es) 2021-05-27
CN113527512A (zh) 2021-10-22
IL243749A0 (en) 2016-04-21
US20210079051A1 (en) 2021-03-18
EP3027642A1 (en) 2016-06-08
CN105980400A (zh) 2016-09-28
CR20160097A (es) 2016-07-29
MX2016001164A (es) 2016-07-26
JP2021113219A (ja) 2021-08-05
MX2019012848A (es) 2019-11-28
MA38873A1 (fr) 2017-09-29
UA116665C2 (uk) 2018-04-25
CA2918624A1 (en) 2015-02-05
EA037355B1 (ru) 2021-03-17
AR097181A1 (es) 2016-02-24
KR102376451B1 (ko) 2022-03-23
KR20240000642A (ko) 2024-01-02
PT3027642T (pt) 2020-10-30
EA202092386A1 (ru) 2021-04-30
JP6509852B2 (ja) 2019-05-08
CL2016000249A1 (es) 2016-07-22
MX369152B (es) 2019-10-30
DK3027642T3 (da) 2020-11-02
JP2023116723A (ja) 2023-08-22
CN105980400B (zh) 2021-05-07
EP3027642B1 (en) 2020-08-19
EP3763734A1 (en) 2021-01-13
AU2014296107B2 (en) 2018-07-26
KR20160038896A (ko) 2016-04-07
BR112016002213A2 (pt) 2017-08-29
EA201690297A1 (ru) 2016-06-30
CA2918624C (en) 2024-02-13
HUE050630T2 (hu) 2020-12-28
KR20220038829A (ko) 2022-03-29
LT3027642T (lt) 2020-10-12
PE20160189A1 (es) 2016-05-06
US20160168213A1 (en) 2016-06-16
JP6877478B2 (ja) 2021-05-26
AU2014296107A1 (en) 2016-02-04
AP2016009011A0 (en) 2016-01-31
TWI648401B (zh) 2019-01-21
US10894814B2 (en) 2021-01-19
NZ717030A (en) 2022-04-29
CY1123836T1 (el) 2022-03-24
IL243749B (en) 2018-06-28
HK1225738A1 (zh) 2017-09-15
SI3027642T1 (sl) 2020-11-30
PH12016500208A1 (en) 2016-04-25

Similar Documents

Publication Publication Date Title
UY35686A (es) Construcciones del factor de diferenciación de crecimiento 15 (gdf-15)
EP3683228A3 (en) Growth differentiation factor 15 (gdf-15) polypeptides
MX343729B (es) Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos.
CR20160240A (es) Sistemas y métodos para la manufactura del marco de una cánula
AR099912A1 (es) Derivados de exendina-4 como agonistas dobles de glp1 / gip o triples de glp1 / gip / glucagon
DOP2015000185A (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos
BR112016023039A2 (pt) agonistas duplos dos receptores de glp-1 / glucagon derivados de exendina-4
EA201590715A1 (ru) Производные эксендина-4 как двойные агонисты glp1/глюкагона
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
WO2013033452A3 (en) Fgf21 for use in treating type 1 diabetes
WO2015034812A3 (en) A new ketogenic diet and its use in treating the critically ill
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
NI201500057A (es) Métodos para reducir riesgos asociados con insuficiencia cardiaca y factores asociados
EA201792030A1 (ru) Лечение пациентов с сахарным диабетом 2 типа
BR112017003644A2 (pt) métodos de tratamento de distúrbios do sono e para regular produção de melatonina.
CR20170376A (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida
TH168762A (th) สิ่งที่สร้างขึ้นเป็นโกรทดิฟเฟอเรนชิเอชันแฟคเตอร์ 15 (gdf-15)
Christanti Factors Affecting Investment Policy Implementation: Case Study of the Yogyakarta Special Region’s Investment Climate Improvement
EA202090988A1 (ru) Способы лечения синдрома фелан-макдермид с помощью дибензодиазепинонов фарнезила
Fu et al. Influences of Social Status, Control, and Perfectionism on International Students' Career Development
RU2014153935A (ru) Способ оздоровления организма человека
Srivastava et al. D27 MITOCHONDRIA: LIVE AND LET DIE: Mkk3 Mediates The Inflammatory Response Through Modulation Of Mitochondrial Function
Hoque et al. Concept of Peace and Social Justice as Reflected in Al Adalat Al Ijtimaiya Fi Al Islam and Al Salam Al Alami wa Al Islam of Sayyid Qutb
Mehdi et al. < The> effect of using Continuous Care Model On sleep quality in people with type 2 diabetes

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20230414

110 Patent granted

Effective date: 20230920